trial
as of 2026-07-01High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
NCTId NCT00297947
at a glance
Phase 2, Phase 3 · Completed
Enrollment 60 (actual)
Sponsored by Manhattan Psychiatric Center
Primary completion 2014-10
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2, Phase 3
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2004-12
Primary completion
2014-10
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Sponsors
Manhattan Psychiatric CenterLead Sponsor
Nathan Kline Institute for Psychiatric ResearchCollaborator
Investigators
2
Jean-Pierre Lindenmayer, MDPrincipal Investigator
Leslie L Citrome, MD, MPHPrincipal Investigator
Sites
2 total
New York, United StatesOrangeburg, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
60
Phase
PHASE2,PHASE3
Primary Completion Date
2014-10
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
indication
investigator